CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Atorvastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00327691
NCT00327691Phase 4Completed
CompareCT.gov

The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD

Pfizer·interventional·Posted May 18, 2006·Updated May 3, 2007

In Brief

A Phase 4 clinical trial evaluating Atorvastatin for Cardiovascular Disease and 2 related conditions. Completed, across 314 sites in 14 countries.

Detailed Summary

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Countries, Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, South Africa, Spain, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 4CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 18, 2006
Enrollment StartApr 1, 1998
Study CompletionAug 1, 2004
TodayJul 2, 2026
Posted 20.1 years ago

Interventions

Atorvastatindrug